SCHEMBL5871119

SCHEMBL5871119

CC(=O)Nc1ccc2cc(C)n(C3CCN(CCCCc4ccc(F)cc4)CC3)c2c1

nearest known ligand 0.48

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 10/20 0.48
CACNA1G O43497 3/20 0.45
CACNA1H O95180 3/20 0.45
HTR2A P28223 2/20 0.44
HTR1A P08908 1/20 0.44
DRD2 P14416 1/20 0.44
HTR2C P28335 1/20 0.44
HTR7 P34969 1/20 0.44
DRD3 P35462 1/20 0.44
KDM4E B2RXH2 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
OPRM1 P35372 1/20 0.42
CCR3 P51677 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5871240 0.97 MCHR1 (0.47) MCHR1CACNA1GCACNA1HHTR2AHTR1A
SCHEMBL5871548 0.94 MCHR1 (0.46) MCHR1CACNA1GHTR2AHTR1AHTR2C
SCHEMBL5871162 0.85 HTR2A (0.43) CACNA1GHTR2AHTR1AHTR2CHTR7
SCHEMBL5871603 0.85 HTR2A (0.43) CACNA1GHTR2AHTR1AHTR2CHTR7
SCHEMBL5871474 0.84 OPRM1 (0.46) MCHR1DRD2KDM4EOPRM1
SCHEMBL5871941 0.84 KDM4E (0.45) MCHR1HTR2AHTR1ADRD2HTR2C
SCHEMBL5872027 0.84 CACNA1G (0.49) MCHR1CACNA1GCACNA1HHTR2AHTR1A
SCHEMBL5871036 0.84 HTR2A (0.43) MCHR1HTR2AHTR1ADRD2HTR2C
SCHEMBL5871451 0.84 ALDH1A1 (0.42) CACNA1GHTR2AHTR1AHTR2CHTR7
SCHEMBL7225051 0.84 MCHR1 (0.48) MCHR1HTR2AHTR1ADRD2HTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579881-B2 Indoles EISAI CO., LTD. (JP) 2003-06-17 US claimed
US-20020019531-A1 Indoles EISAI CO., LTD. 2002-02-14 US claimed
EP-0976732-A1 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES Eisai Co., Ltd. (JP) 2000-02-02 EP claimed
US-7071201-B2 Serotonin antagonism; muscle relaxant for myotonia; such as 1-(1-(2-(4-methoxyphenyl)ethyl)piperidin-4-yl)-7-methoxy-1,2,3,4 -tetrahydroquinoline EISAI CO., LTD. (JP) 2006-07-04 US disclosed
EP-0976732-B1 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES EISAI CO LTD (JP) 2004-11-24 EP disclosed
US-6579881-B2 Indoles EISAI CO., LTD. (JP) 2003-06-17 US disclosed
US-6448243-B1 SEROTONIN ANTAGONIST FOR TREATING, AMELIORATING AND PREVENTING SPASTIC PARALYSIS OR CENTRAL MUSCLE RELAXANTS FOR AMELIORATING MYOTONIA EISAI CO., LTD. (JP) 2002-09-10 US disclosed
US-20020086999-A1 Certain quinoline derivatives EISAI CO., LTD. 2002-07-04 US disclosed
US-20020019531-A1 Indoles EISAI CO., LTD. 2002-02-14 US disclosed
EP-0976732-A1 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES Eisai Co., Ltd. (JP) 2000-02-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019531-A1 Indoles INMT, MUSK, MB MCHR1 325/4885CACNA1G 163/4885CACNA1H 124/4885
US-20020086999-A1 Certain quinoline derivatives CHRM1, CHRNA5, CHRNA4 MCHR1 588/4885CACNA1G 118/4885CACNA1H 85/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.